The standard builds a risk-sensitive capital framework around four core concepts: (1) the Internal Capital Adequacy Assessment Process (ICAAP); (2) the capital base and its eligible components; (3) the Prudential Capital Requirement (PCR) calculated as prescribed capital plus supervisory adjustments; and (4) supervisory control and disclosure.

ICAAP: The Board must ensure a documented, Board‑approved ICAAP appropriate to the company’s size, business mix and complexity (paras 10-13). The ICAAP must include policies, procedures and systems for identifying, measuring, monitoring and managing risks and capital; specific capital targets; triggers and remediation plans for potential breaches; stress testing and scenario analysis; reporting to the Board and senior management; and policies for material risks not captured by explicit regulatory capital charges (para 13). An ICAAP summary statement must describe objectives, key assumptions and methodologies, triggers for review, review policy and the basis of measurement of capital (paras 13-14). ICAAPs must be independently reviewed at least every three years (para 15) and an ICAAP report must be supplied to APRA annually within three months of the reporting period (paras 16-18). The Board must also provide a declaration, signed by the CEO, about adherence to the ICAAP and the adequacy of capital targets (para 18).

Capital base and measurement: The standard distinguishes capital quantity and capital quality. Paragraphs 19-21 instruct assessing not only quantum but the permanence, availability to absorb losses, absence of servicing charges and subordination to policyholders and creditors. LPS 112 is referenced as defining eligible capital categories (Common Equity Tier 1, Additional Tier 1, Tier 2), transition amounts and regulatory adjustments; it is the source of detailed measurement and restrictions (paras 19-21).

Prudential Capital Requirement (PCR) and Standard Method: PCR is the regulatory required level of capital (para 22). Funds and companies must keep capital base in excess of PCR at all times (para 23). The Standard Method constructs the prescribed capital amount as the sum of four charges (Insurance Risk, Asset Risk, Asset Concentration Risk, Operational Risk), less an aggregation benefit (which allows limited diversification between asset and insurance risk using a fixed 20 per cent correlation), plus a combined stress scenario adjustment (paras 29-41). The Insurance and Asset Risk Charges are to be calculated according to LPS 115 and LPS 114 respectively; concentration and operational charges are from LPS 117 and LPS 118 (paras 31-35). Attachment B specifies the combined stress scenario adjustment process and requires the single scenario to apply adjusted stresses simultaneously to asset and insurance risks (Attachment B paras 1-10).

Supervisory discretion and adjustments: APRA may adjust the Standard Method calculation for a particular fund if it considers the method does not produce an appropriate outcome, or the company has used inappropriate judgement (para 42). APRA may also add a supervisory adjustment to PCR for prudential reasons (para 43). APRA may issue written notices to adjust or exclude specific requirements in the Prudential Standard for a life company (para 54). Supervisory adjustments are not to be disclosed by the life company (para 47).

Disclosure and controls on capital reductions: Companies must publish specified capital composition items (Common Equity Tier 1, Additional Tier 1, Tier 2, regulatory adjustments), total capital base, prescribed capital amount and capital adequacy multiple for both company and each fund at least annually, and information must be readily accessible (paras 44-46). Planned capital reductions require APRA written approval and supporting two‑year forecasts and assurance that post-reduction capital remains adequate (paras 48-51). Notification obligations require companies to advise APRA as soon as practicable of PCR breaches or prospective breaches, significant departures from ICAAP, or significant adverse changes in capital base or PCR (para 53).

Special regimes and adjustments: Variable annuities are treated as a special case requiring more sophisticated stochastic or scenario modelling that simultaneously considers asset and insurance risks, addresses hedging effectiveness, and applies an effectiveness factor E (Attachment A paras 1-11). The prescribed capital amount floor of $10 million for the life company is an explicit quantitative boundary (para 25).

Primary regulated entities: The standard applies to all life companies registered under the Life Insurance Act 1995, explicitly including friendly societies (paras 1-3). For a life company other than a friendly society, the standard applies separately to each statutory fund, the shareholders’ fund (general fund), and the life company as a whole (para 3(a)). For a friendly society, it applies to each approved benefit fund, its management fund (general fund), and the friendly society as a whole (para 3(b)). The application to Eligible Foreign Life Insurance Companies (EFLICs) is limited to business carried on through Australian statutory funds (para 4; footnote to s16ZD of the Act).

Internal decision-makers and owners: The Board and senior management of life companies bear responsibility for capital management governance, ICAAP design and implementation and for ensuring capital adequacy at both fund and consolidated levels (paras 8-9, 10-14). The CEO must sign the ICAAP report declaration approved by the Board (para 18). Shareholders are affected indirectly through limits on distributions and capital reductions that require APRA approval (paras 48-51). For EFLICs, the standard’s reductions-in-capital requirements apply at each Australian statutory fund level (footnote at para 49).

Service providers and modelling vendors: Actuarial teams, risk-modelling functions, external model validators and auditors will be materially engaged. Attachment A imposes specific modelling standards for variable annuity exposures (Attachment A paras 2-7). The requirement that the ICAAP be independently reviewed at least every three years (para 15) creates demand for suitably independent reviewers.

APRA and prudential supervisors: APRA is the decision-maker for supervisory adjustments, approvals for capital reductions, and the regulator to which ICAAP reports and notifications must be provided (paras 16-18, 42-51, 53-54). APRA also prescribes the detailed measurement of capital in LPS 112 and the methods for specific charges in LPS 114, 115, 117 and 118 (paras 20, 31-35).

Policy owners and market participants: Policy owners gain transparency through mandatory public disclosure of capital composition and capital adequacy multiples at company and fund level (paras 44-46). However, supervisory adjustments determined by APRA are excluded from disclosure (para 47), limiting visibility of supervisor-imposed add-ons. Market participants (creditors, counterparties, potential acquirers) will use the required disclosures to assess solvency and capital buffers.

New entrants and firms with specific product types: Firms writing variable annuities face additional modelling and capital requirements: they must obtain APRA approval of the method to calculate prescribed capital for a statutory fund intending to issue variable annuities before issuing policies (para 27). New entrants without 12 months’ experience must set the hedging effectiveness factor E at no greater than 0.30 (Attachment A para 7(c)), which is a binding operational constraint for new providers of such products.

Other affected regimes: The standard cross‑references other prudential standards (LPS 112, 114, 115, 117, 118, LPS 001 Definitions) and reporting rules under the Financial Sector (Collection of Data) Act 2001 insofar as definitions like “financial year” reference those returns (para 49 footnote). Entities subject to multiple APRA standards will need to align capital measurement and reporting across those instruments.

Duties allocated to the Board and senior management

• Ensure adequate capital for the life company and each fund commensurate with scale, nature and complexity of business and risk profile (paras 8-9). The duty is explicit and continuous: capital must be adequate "at all times" relative to PCR (para 23).
• Approve and maintain a documented ICAAP commensurate with size and complexity (paras 10-13). The ICAAP must include policies for identification, measurement and management of risks, a capital strategy with targets and sourcing plans, triggers and remediation actions for breaches, stress testing, reporting processes, and policies addressing material unmodelled risks (para 13).
• Ensure the ICAAP summary statement is prepared and contains prescribed content (para 14).
• Ensure independent ICAAP review at least every three years and address recommendations (para 15).
• Provide an annual ICAAP report to APRA and a Board-approved CEO-signed declaration about compliance with ICAAP and adequacy of capital targets (paras 16-18).

Duties related to capital measurement and maintenance

• Maintain a capital base meeting quality criteria (permanent, loss-absorbing, no unavoidable servicing charges, subordinate on winding-up) and apply the adjustments and exclusions specified in LPS 112 (paras 19-21).
• Ensure capital base exceeds PCR for each fund and the company at all times; compute PCR using the Standard Method and any APRA supervisory adjustments (paras 22-25, 29-41, 43).
• For statutory funds with variable annuities, calculate prescribed capital using Attachment A modelling methods and obtain APRA approval for the method before issuing such policies (paras 26-27; Attachment A).

Disclosure and notification duties

• Publish the specified company-level and fund-level capital metrics at least annually and make them readily accessible to policy owners and market participants (paras 44-46).
• Do not disclose APRA-imposed supervisory adjustments (para 47).
• Obtain APRA written approval before planned reductions in company capital base; provide at least two years’ forward forecast and satisfy APRA that capital will remain adequate post-reduction (paras 48-51).
• Notify APRA as soon as practicable of breaches or prospective breaches of PCR, significant departures from ICAAP, or significant adverse changes in capital base or PCR, including remedial actions (para 53).

Supervisor’s rights and powers

• APRA may, in writing, adjust any aspect of prescribed capital calculations or determine a supervisory adjustment to PCR for prudential reasons and require a life company to comply with adjusted calculations (paras 42-43).
• APRA may, by written notice, adjust or exclude a specific requirement in the Prudential Standard for a particular life company (para 54).
• APRA may prescribe or approve values (for example, the E factor for variable annuity hedging) where APRA is satisfied a company’s adopted value is inappropriate (Attachment A para 10).

Rights and discretions for life companies

• Life companies can take into account materiality in calculating capital base and prescribed capital amount (para 52). That introduces a degree of proportionality into the calculations, but it remains subject to supervisory review.
• A life company may rely on a group ICAAP for its own ICAAP where the Board is satisfied the group ICAAP meets the standard criteria in respect of the life company (para 12).

Compliance and review rights

• A life company must inform APRA if it intends to rely on a previous APRA exemption or exercise of discretion under an earlier version of the Prudential Standard (para 55). This imposes an affirmative duty to confirm historical discretions remain applicable.

Contractual and market effects arising from duties

• The requirement to maintain capital at fund level separately from company level affects internal capital allocation, capacity to transfer capital between funds and dividend/distribution strategies (paras 2-3, 23-25, 48-51). The standard does not itself prescribe intra-company transfer mechanics but imposes limits via capital adequacy and APRA approval for reductions.

The Prudential Standard is a determination made by APRA under the Life Insurance Act 1995 (Authority). The instrument itself does not prescribe criminal penalties or monetary fines within its text; it creates obligations and enumerates supervisory powers and administrative controls that enable APRA to require compliance (paras 42-43, 48-51, 53-55). Enforcement of the standard therefore operates through APRA’s supervisory toolkit and the regulatory framework of the Life Insurance Act, rather than by specifying new statutory penalty amounts in this document.

Forms of supervisory enforcement and de facto sanctions implied by the instrument

• Supervisory adjustments to PCR and adjustments to prescribed capital calculations (paras 42-43): APRA can impose written adjustments that a life company must comply with. Non-compliance with such a written determination is a violation of an APRA direction and would expose the life company to APRA supervisory responses under the Life Insurance Act (paras 42-43). The instrument requires compliance with adjusted calculations but does not itself set out consequences; enforcement would flow from the Act and broader APRA powers.
• Restrictions on capital reductions (paras 48-51): APRA can refuse written approval for planned reductions in capital base. Non-approved reductions would breach the Prudential Standard and could be the basis for supervisory action; the instrument requires companies to obtain APRA approval and to demonstrate post-reduction adequacy.
• Notification obligations (para 53): Firms must inform APRA as soon as practicable of breaches or prospective breaches of PCR, significant departures from ICAAP or significant adverse capital changes. Failure to notify is a breach of the Prudential Standard and may trigger supervisory measures.
• Adjustments and exclusions (para 54): APRA may, by notice, amend requirements for a life company. The power to issue such notices gives APRA the capacity to tailor obligations and to impose specific requirements; failure to comply with such a notice would be a direct breach.
• Public disclosure obligations (paras 44-46): The Prudential Standard requires publication of capital metrics. While the instrument does not set a penalty, non-publication or misleading publication could be the subject of supervisory action and other regulatory compliance consequences under broader financial services law.

Interaction with statutory enforcement framework

• Although this Prudential Standard does not itself list penalties, it is made under the Act (paragraph 230A(1)(a)). APRA’s enforcement powers under the Life Insurance Act (and other relevant financial services statutes and standards) provide statutory mechanisms for administratively responding to breaches , for example, directions, conditions on registration, enforcement notices and, where relevant, civil penalties or other remedies available in the Act. The Prudential Standard’s obligations therefore function within that larger statutory enforcement architecture.

Practical enforcement risks and consequences for firms

• Non‑compliance may trigger APRA supervisory interventions that can restrict business activities (for example, denial of capital reductions, remedial plans, or conditions on licence operations). APRA’s capacity to impose supervisory adjustments to PCR (para 43) can materially increase a firm’s regulatory capital requirement without legislative amendment, creating immediate balance sheet and strategic consequences.
• The instrument’s requirement for an annual ICAAP report and Board declaration (paras 16-18) means incorrect or misleading statements could expose boards and senior officers to regulatory scrutiny under other legal frameworks applicable to public statements and statutory obligations.

In sum, the instrument creates binding prudential duties and confers supervisory powers on APRA that enable administrative enforcement and regulatory control. The instrument does not itself enumerate criminal or civil penalty schedules; enforcement will be effected through the Life Insurance Act and APRA’s statutory powers and supervisory responses.

Reference to Life Insurance Act 1995: The Prudential Standard is made under paragraph 230A(1)(a) of the Life Insurance Act 1995 (Authority) and applies to entities registered under that Act (Authority; paras 1-3). Consequently, the standard functions as part of APRA’s prudential framework under the Act and must be read and applied in that statutory context.

Cross-references to other prudential standards: LPS 110 delegates detailed capital measurement and component definitions to other prudential standards:

• LPS 112 Capital Adequacy: Measurement of Capital is the source for what forms of capital are eligible, the categorisation into Common Equity Tier 1, Additional Tier 1 and Tier 2, transition amounts and regulatory adjustments (paras 19-21; s44-45 reference Common Equity Tier 1, Additional Tier 1, Tier 2 and regulatory adjustments).
• LPS 114 informs the Asset Risk Charge (para 33).
• LPS 115 informs the Insurance Risk Charge and the definition of adjusted stress margins referenced in Attachment B (paras 31, Attachment B note 10; Attachment B para 5 references adjusted stress margins as defined in LPS 115).
• LPS 117 covers the Asset Concentration Risk Charge (para 34).
• LPS 118 covers the Operational Risk Charge (para 35). These cross-references mean that practical implementation requires combined compliance with multiple LPS instruments. Any change in those referenced standards can alter capital measurement under LPS 110 without amendment to LPS 110 itself.

Interaction with financial reporting and data collection regimes: The Prudential Standard references the reporting standards under the Financial Sector (Collection of Data) Act 2001 for definitions such as "financial year" used in the dividends test for reductions in capital (para 49 footnote). This ties the timing and metrics used in capital reduction approvals to statutory reporting under that data collection regime.

APRA discretion and administrative law: The standard grants APRA discretionary powers to adjust prescribed calculations, impose supervisory adjustments and issue notices to adjust or exclude requirements (paras 42-43, 54). Those powers sit within the administrative law framework; decisions taken by APRA under these provisions will be subject to the standard processes of administrative decision‑making, internal APRA processes and potential judicial review under general administrative law, albeit the instrument itself does not address judicial review (paras 42-43, 54).

Overlap with company law and distribution law: The standard requires APRA approval for certain capital reductions and treats dividends exceeding after-tax earnings as reductions in capital base where they exceed after-tax earnings after taking into account payments on senior capital instruments (paras 48-49(c)). That interacts with directors’ duties under company law regarding solvency and distributions. The standard imposes an administrative permissioning overlay: even where a dividend might otherwise be permitted under company law, APRA approval may be required in order not to breach the Prudential Standard.

International considerations and foreign firms: For Eligible Foreign Life Insurance Companies (EFLICs), the standard applies only to Australian statutory funds (para 4). For EFLICs, reductions-in-capital requirements apply at the level of each statutory fund of the Australian operations (footnote at para 49). The standard therefore applies the prudential requirements that are domestic in effect to the Australian-sited funds of foreign groups rather than to entire parent-group solvency positions.

Relationship to market disclosure regimes: The mandatory publication of capital metrics (paras 44-46) will interact with continuous disclosure obligations applicable to listed entities under the Corporations Act and ASX Listing Rules, where those apply; however, APRA expressly precludes disclosure of supervisory adjustments (para 47), which will create an information asymmetry between regulators and the market for those items.

Pre-existing discretions and transitional arrangements: The standard requires firms to contact APRA before relying on previous exemptions or discretions granted under earlier versions of the standard (para 55). This creates an interaction point with historical APRA exercises of discretion and any previously granted arrangements.

Immediate change: The instrument revokes Prudential Standard LPS 110 Capital Adequacy made under Life Insurance (prudential standard) determination No. 2 of 2012 and replaces it with the current determination No. 6 of 2023 (front matter). The new determination commences on 1 July 2023 (front matter; Application and commencement para 5).

Authority for amendment: The instrument is made under paragraph 230A(1)(a) of the Life Insurance Act 1995 (Authority). The revocation of the previous standard is effected under subsection 230A(5) of the Act as noted in the front matter (front matter).

Transitional and continuity notes in the text: The standard contains a specific paragraph requiring a life company to contact APRA if it seeks to rely on a previous exemption or other exercise of discretion made by APRA under a previous version of this Prudential Standard (para 55). That indicates APRA will consider historical discretions on a case-by-case basis and firms should not assume automatic carry-over of any prior exemptions or discretions.

Referenced consequential standards: LPS 110 is explicitly dependent on and cross-references LPS 112, 114, 115, 117 and 118 for detailed measurement rules and methodologies. Any future amendments to those standards will affect how LPS 110 operates in practice. The instrument does not itself contain transitional schedules for each referenced LPS; it treats those instruments as part of the broader prudential framework.

No amendment timeline or staged implementation in the instrument: Apart from the commencement date (1 July 2023), the instrument does not specify phased implementation windows, grandfathering, or staged compliance obligations in the text. The only temporal obligations specified are the annual ICAAP reporting timing (paras 16-18), the triennial ICAAP review (para 15), and forecast horizons for capital reduction approvals (para 50). Where transitional arrangements are relevant (for example, transition amounts approved by APRA under capital adequacy standards), the disclosure requirements expressly require identifying any transition amount approved by APRA (footnote to para 45).

What the instrument does not record about amendment history: The instrument revokes the prior named determination and replaces it; it does not include an internal history of prior amendments, dates of earlier versions beyond the 2012 instrument mention, nor does it list prior APRA discretionary exercises. Firms must therefore rely on APRA records and prior determinations for a complete historical trail. The instrument’s paragraph 55 requires confirmation from APRA for reliance on past discretions, acknowledging that historical practice matters but will be validated administratively.

The text of this Prudential Standard does not cite or summarise any judicial decisions, nor does it record any litigation history (the instrument contains no case references). There is therefore no litigation history embedded in the instrument itself.

The instrument does create several discrete administrative decision points that are commonly litigated in prudential contexts, namely:

• APRA’s written adjustments to prescribed capital calculations or imposition of supervisory adjustments (paras 42-43).
• APRA’s written approval or refusal of planned reductions in the capital base, including the assessment of dividend distributions relative to after-tax earnings (paras 48-51).
• APRA’s exercise of discretion to adjust or exclude specific requirements by written notice (para 54).

Those provisions create potential grounds for dispute about the scope of APRA’s discretion, the adequacy of reasons for a supervisory adjustment or adjustment to the Standard Method, and procedural fairness in APRA decision-making. The Prudential Standard itself does not provide an internal dispute-resolution mechanism for challenging APRA determinations under paras 42-43 or notices under para 54; any challenge to APRA action would therefore sit against the statutory and administrative law framework applicable to APRA decisions under the Life Insurance Act and general public law.

Practical litigation-related considerations that follow from the instrument (textual basis only)

• The standard requires life companies to comply with APRA’s adjusted calculations in writing (para 42) and supervisory adjustments (para 43). Because the instrument makes the requirement of compliance explicit, firms facing an APRA adjustment must comply while they consider administrative review or external remedies. That sequencing can have immediate balance-sheet consequences, including capital increases, and therefore tight time pressures to seek remedies.
• The prohibition on disclosing supervisory adjustments (para 47) limits a firm’s ability to brief the market about APRA-imposed capital add-ons. That could become a contested issue where firms argue for the right to disclose material information, but the Prudential Standard makes non-disclosure mandatory.
• The requirement to obtain APRA approval for capital reductions and to present forecasts that demonstrate post‑reduction adequacy (paras 48-51) sets an administratively reviewable precondition on actions (dividends, buybacks, redemptions) that affect shareholder value. Any refusal or conditioned approval may give rise to commercial disputes or legal challenges, but the instrument itself does not specify dispute processes.

Because the instrument does not record cases or litigation, counsel and compliance teams should not treat the standard as carrying any settled judicial interpretations; instead, the legal risk assessment should rely on the text of the standard, the Life Insurance Act, and applicable administrative law principles outside this instrument. Firms should also examine APRA guidance, prior APRA determinations and any published APRA administrative decisions for precedential administrative practice, noting that the standard explicitly requires dialogue with APRA about historical discretions (para 55).

1. Fund-level application and company-level aggregation: LPS 110 applies separately to each statutory fund and to the company as a whole (para 3). This dual-level requirement constrains capital allocation and can produce binding capital needs even if consolidated capital is adequate. Firms cannot assume company-level capital adequacy obviates fund-level deficits.

2. $10 million minimum prescribed capital: Regardless of the outcome of the Standard Method, a life company’s prescribed capital amount cannot be less than $10 million (para 25). Small firms or narrow specialisation strategies cannot rely on extremely low calculated capital without meeting this statutory floor.

3. APRA’s written adjustments are binding: APRA may adjust any aspect of the prescribed capital calculation for a fund if it considers the Standard Method does not produce an appropriate outcome or the company has used inappropriate judgement (para 42). The company must comply with the adjusted calculation once APRA writes it. That creates an asymmetric unilateral supervisory power to increase required capital without changing the standard by instrument.

4. Supervisory adjustments are not disclosable: Life companies must not disclose any supervisory adjustment determined by APRA (para 47). This creates an information asymmetry between APRA and the public and can complicate market communication around capital positions.

5. Variable annuities modelling and E factor caps: Statutory funds with variable annuity business must use stochastic or adequate scenario models that consider asset and insurance risk simultaneously and address hedging effectiveness (Attachment A paras 2-6). The effectiveness factor E cannot exceed 0.70, and firms with less than 12 months of experience must use E ≤ 0.30 (Attachment A para 7). APRA can require a specific E if it deems the firm’s choice inappropriate (Attachment A para 10). For new entrants, the 0.30 cap is a practical constraint that increases capital needs relative to incumbents.

6. Limits to management action in stress scenarios: Management actions that reduce policy benefits can only be assumed up to specified limits; firms must increase prescribed capital if aggregated management actions would reduce policy benefits below those limits (para 40). Attachment B further constrains the extent to which discretionary management actions can be taken in the combined stress scenario (Attachment B para 9).

7. Aggregation benefit limited and formulaic: The aggregation benefit uses a fixed correlation of 20 per cent between Asset and Insurance Risk Charges (paras 36-37). Asset Concentration Risk Charge and Operational Risk Charge are excluded from the aggregation benefit (para 38). Firms should not expect broader diversification credit beyond this defined metric.

8. Disclosure granularity: The standard mandates detailed disclosure items at both company and fund level, including the components of each fund’s prescribed capital amount and capital adequacy multiples (paras 44-46). For funds with variable annuity business, separate disclosure of Asset and Insurance Risk Charges and aggregation benefit is not required (footnote to para 45); practitioners must note that exception when compiling published figures.

9. Reductions in capital base include dividends that exceed after-tax earnings: A dividend aggregate exceeding after-tax earnings is considered a reduction in the capital base (para 49(c)). The definition of “financial year” for this test refers to reporting to APRA under the Financial Sector (Collection of Data) Act (footnote to para 49). Directors cannot treat distributions as neutral from a prudential perspective simply because company law may permit them.

10. ICAAP governance and reporting deadlines: The ICAAP must be Board-approved and documented; the firm must supply an annual ICAAP report to APRA within three months of the end of the ICAAP reporting period and include a Board-approved declaration signed by the CEO (paras 10, 16-18). These are formalities with compliance consequences; the Board and CEO signature are specific procedural requirements.

11. Independent review frequency and scope: The ICAAP must be independently reviewed at least every three years, and the review must be sufficient to reach a view on ICAAP adequacy and effectiveness (para 15). The standard requires operational independence of the reviewers from capital-management operations; this can limit who may provide review services.

12. Materiality permitted but not carte blanche: The standard permits taking materiality into account (para 52), but materiality is defined relative to producing misleading results. Supervisory scrutiny will likely examine materiality judgements in capital calculations, particularly where they materially affect PCR or published metrics.

13. APRA notices and historical discretions: APRA may adjust or exclude requirements by notice (para 54), and firms must contact APRA to rely on prior discretions (para 55). Firms should not assume historical practices remain authorised without APRA confirmation.

14. EFLICs , Australian statutory funds only: For Eligible Foreign Life Insurance Companies, the standard applies to Australian statutory funds but not to other parts of the EFLIC’s business (para 4). Nonetheless, reductions in capital base requirements apply at the statutory fund level for Australian operations (footnote to para 49). Foreign parent capital supports are therefore not automatically recognised; local statutory fund metrics matter.

Governance and Board duties

• Board charter and minutes should record explicit responsibility for capital management and approval of the ICAAP (paras 8-11). Ensure the ICAAP is formally approved on initial adoption and upon significant change (para 10(b)).
• Produce an ICAAP summary statement that addresses the items in paragraph 14: objectives and time horizon, key assumptions and methodologies (including stress testing approaches), triggers for review, the review policy and responsibilities, and the basis of capital measurement (para 14).

ICAAP design and documentation

• Implement documented policies, procedures, systems and personnel to identify, measure, monitor and manage risks and capital continuously (para 13(a)). The scope must reflect the life company’s size, business mix and complexity (para 11).
• Set explicit capital strategy and targets, linked to Board risk appetite and regulatory capital requirements. Include plans for sourcing additional capital and contingency funding (para 13(b)).
• Establish triggers and pre-planned remedial actions for potential and prospective breaches of PCR (para 13(c)).
• Integrate stress testing and scenario analysis into capital planning (para 13(d)) and ensure stress scenarios align with the combined stress scenario adjustment mechanics in Attachment B (Attachment B paras 1-7).

ICAAP review and reporting

• Commission independent ICAAP reviews no less than every three years; ensure operational independence of reviewers (para 15).
• Prepare the ICAAP report annually and lodge with APRA no later than three months after the end of the reporting period (para 16). The ICAAP report must include current and three-year projected capital levels, comparison of outcomes to prior plans, description of material changes, stress testing outcomes, capital usage breakdowns, changes in risk profile, review outcomes and references to supporting documentation (para 17).
• Obtain Board approval and CEO signature on the required declaration that capital management has been undertaken in accordance with ICAAP, that capital targets are adequate, and that the ICAAP report is accurate in all material respects (para 18).

Capital measurement and reserves

• Align capital measurement with LPS 112. Review and apply the eligibility criteria for Common Equity Tier 1, Additional Tier 1 and Tier 2 capital and apply regulatory adjustments specified in LPS 112 (paras 19-21; paras 44-45 disclosure items).
• Ensure accounting adjustments (deferred tax assets, goodwill, intangibles, allowances for future transactions) are treated as LPS 112 prescribes for supervisory purposes (para 21).

Compute PCR according to the Standard Method

• Calculate Insurance Risk Charge per LPS 115 and Asset Risk Charge per LPS 114 (paras 31-33). Ensure the Asset Concentration Risk Charge and Operational Risk Charge follow LPS 117 and LPS 118 respectively (paras 34-35).
• Apply the aggregation benefit formula using A for Asset Risk Charge, I for Insurance Risk Charge and a 20 per cent correlation; do not include Asset Concentration or Operational Risk charges in the aggregation benefit (paras 36-38).
• Calculate the combined stress scenario adjustment per Attachment B; ensure the single scenario applies adjusted insurance and asset stresses simultaneously and that the combined stress scenario adjustment is not negative (Attachment B paras 1-2).

Special handling for variable annuities

• If issuing variable annuities, obtain APRA approval for the method to be used for calculating the prescribed capital amount for the statutory fund before issuing policies (paras 26-27).
• Build stochastic or adequate scenario-based models that simultaneously consider asset and insurance risks, hedging implementation uncertainty, hedging effectiveness, access to hedge instruments, matching horizons, discretions, and management corrective action (Attachment A paras 2-5).
• Determine E in line with Attachment A and document the justification and data supporting the selected E; cap E at 0.70, and if less than 12 months of experience exists set E ≤ 0.30 (Attachment A para 7). Be prepared to accept an APRA-specified E if APRA deems the company’s value inappropriate (Attachment A para 10).

Disclosure and public communication

• Publish at least annually the company-level metrics listed in paragraph 44 and the fund-level metrics listed in paragraph 45, and make them readily accessible to policy owners and market participants (paras 44-46).
• Do not disclose APRA supervisory adjustments (para 47). Ensure external communications and investor materials are aligned with this constraint and that legal and compliance review occurs prior to publication.

Capital reductions and distributions

• Before any planned reduction in capital base (including buybacks, redemptions, trading outside agreed arrangements, or dividends exceeding after-tax earnings), obtain APRA written approval (paras 48-49). For EFLICs, apply reductions rules at the statutory fund level for Australian operations (footnote to para 49).
• Supply APRA with a forecast showing projected future capital position (including PCR) for at least two years and evidence the capital base will remain adequate post-reduction (paras 50-51).

Notifications and recordkeeping

• Notify APRA as soon as practicable of actual or prospective PCR breaches, significant departures from ICAAP, and any significant adverse changes in the capital base or PCR; include remedial actions and timing (para 53).
• Maintain contemporaneous records of ICAAP documents, stress-testing outputs, model documentation, Board approvals, independent review reports and the annual ICAAP report; make documentation available to APRA on request (para 10(a), para 14(f), para 16).

Materiality and judgement

• Where materiality is used in calculations, document the rationale and show that omission or misstatement would not be misleading to users, and be prepared to justify materiality judgements to APRA (para 52).

Engage with APRA proactively

• If a life company intends to rely on historical APRA discretions, contact APRA to confirm reliance is permissible (para 55).
• For novel products, capital models or management actions (e.g., variable annuity hedging, complex reinsurance), engage APRA early to secure clarity on acceptable methodology and to anticipate supervisory adjustments (paras 26-27, Attachment A para 10, para 42).

Operationalise stress and management actions

• When modelling stress scenarios, only assume management actions to the extent they are appropriate, justifiable and equitable in the adverse conditions assumed (Attachment B para 9). Document the limits on assumed management actions and ensure these limits are applied consistently across the Insurance and Asset Risk Charge calculations and the combined stress scenario.

External assurance and validation

• Ensure actuarial models, stochastic valuations and hedging models are subject to appropriate validation and external audit where required by LPS 112, LPS 114, LPS 115 or attachment-specific requirements. The ICAAP review requirement (para 15) contemplates an external independent assessment of the ICAAP and its modelling.

Practical checklist summary (immediate items)

• Board: approve ICAAP and ICAAP summary statement; document capital targets and triggers (paras 10, 13-14).
• Management: implement systems to calculate Standard Method charges per referenced LPS; model combined stress scenario; determine and document aggregation benefit (paras 29-41, Attachment B).
• Reporting: prepare annual ICAAP report and Board/CEO declaration; publish required capital disclosures at least annually (paras 16-18, 44-46).
• Capital actions: obtain APRA written approval before buybacks, redemptions or distributive actions that reduce capital base per paras 48-51.
• Notifications: notify APRA promptly of breaches or prospective breaches and significant departures from ICAAP (para 53).

Adopting these measures and documenting the decisions, assumptions and governance processes will put a life company in the position of being able to demonstrate compliance with LPS 110 and to respond to APRA enquiries or supervisory adjustments.